

Chaînes légères libres d'immunoglobulines et gammopathies Freie Immunglobulin-Leichtketten und Gammopathien

Literatur / Références

- 1 Kyle RA. Multiple myeloma: an odyssey of discovery. *Br J Haematology*. 2000;111:1035–44.
- 2 Kyle RA. The monoclonal proteins: a brief history. *Hematology reports*. 2010;2(s2):1.
- 3 Bradwell AR, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum. *Clin Chem*. 2001;47:673–80.
- 4 Bradwell AR. Serum Free Light Chain Analysis (plus Hevlyte). The Binding Site 5th edition. 2008. On line 6th edition 2010–2011 www.bindingsite.com/news?story=379 (Wikilite.co.uk)
- 5 Gibbs SDJ, Hawkins PN. Biochemical basis of the amyloid diseases. *Br J Hosp Med*. 2010;71:70–5.
- 6 Baden EM et al. Light chain amyloidosis – current findings and future prospects. *Current Protein and Peptide Science*. 2009;10:500–8.
- 7 Snozek CL, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the International Staging System. *Leukemia*. 2008;22:1933–7.
- 8 Greipp PR et al. International Staging System for Multiple Myeloma. *J Clin Oncol*. 2005;23:3412–20.
- 9 Durie BGM, et al. International uniform response criteria for multiple myeloma. *Leukemia*. 2006;20:1467–73.
- 10 Dispenzieri A, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet*. 2010;375:1721–8.
- 11 Drayson MT, et al. Serum-free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. *Blood*. 2001;97:2900–2.
- 12 Leleu X, et al. Serum immunoglobulin free light chains (sFLC) correlates with tumor burden markers in Waldenström macroglobulinemia. *Leuk & Lymphoma* 2008;49:1104–7.
- 13 Leleu X, et al. The role of serum immunoglobulin free light chain in response and progression in Waldenström macroglobulinemia. *Clin Cancer Res*. 2011; 17:3013–8.
- 14 Stankowski-Drengler T, et al. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. *Am J Hematol*. 2010; 85:431–4.
- 15 Richter AG et al. Multiple myeloma with monoclonal free IgG3 heavy chains and free kappa light chains. *Acta Haematol*. 2010;123:158–61.
- 16 Maurer MJ, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohort of patients with diffuse large B-cell lymphomas. *J Clin Oncol*. 2011;29:1620–6.
- 17 Maurer MJ, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. *Blood*. 2011;118:2821–6.
- 18 Terrier B, et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. *Ann Rheum Dis*. 2009;68:89–93.
- 19 Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. *Trends Pharmacol Sci*. 2008;29(4):170-4. Epub 2008 Mar 18.
- 20 Hopper JE et al. Clinical Relapse in Systemic Lupus Erythematosus: Correlation with Antecedent Elevation of Urinary Free-Light-Chain Immunoglobulin. *J Clin Immunol*. 1989;9:338–50.
- 21 Aggarwal R, et al. Serum free light chains as biomarkers for systematic lupus erythematosus disease activity. *Arthritis Care Res (Hoboken)*. 2011; 63:891–8.
- 22 Gottenberg JE, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndrome. *Am Rheum Dis*. 2007;66:23–7.
- 23 Gottenberg JE, et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. *Arthritis Res Ther*. 2009;11:R114.
- 24 Ayliffe MF, et al. Demonstration of changes in plasma cell subsets in multiple myeloma. *Haematologica*. 2007;92:1135–8.
- 25 Trcic RL, et al. Cytogenetics of multiple myeloma. *Coll Antropol*. 2010;34:41–4.
- 26 Katzmann JA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. *Mayo Clin Proc*. 2006;81:1575–8.
- 27 Katzmann JA, et al. Screening panels for detection of monoclonal gammopathies. *Clin-Chem*. 2009;55:1517–22.